Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mass Drug Administration of Tafenoquine for P. Vivax Radical Cure: Safety and Feasibility Study

NCT06575647 is registered in ClinicalTrials.gov with Shoklo Malaria Research Unit as lead sponsor.

NCT NCT06575647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mass Drug Administration of Tafenoquine for P. Vivax Radical Cure: Safety and Feasibility Study
Lead sponsor
Shoklo Malaria Research Unit
Phase
Phase 4
Overall status
Completed
Start date
February 19, 2025
Completion date
October 4, 2025
Enrollment
1,242 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria, vivax, plasmodium vivax, plasmodium vivax malaria